Intuitive Surgical is still expensive, even at a 31x forward P/E that marks its lowest forward multiple in a decade. x.com 

Intuitive Surgical's valuation has become much more reasonable but is still a little too expensive with growth slowing. At its highs it traded at about 18x next-twelve-month revenue, which was nonsense. x.com 

Intuitive Surgical is a high-quality business near its 200-week moving average, the entry point Charlie Munger said would beat the S&P 500 by a wide margin over time. At the cutting edge of robotics and soon AI in healthcare, with no competition, very high barriers to entry and huge switching costs, it deserves a premium. At 34x forward earnings it is expensive but tolerable; about 30x is close to fair value, 25x is cheap and 20x a slam dunk. x.com  x.com  x.com 

Intuitive Surgical does not look cheap at the current price, contrary to the view that it is very tempting, though something could be missing. x.com 

Intuitive Surgical is a great company, but 13-15% growth will probably bring the stock under pressure. x.com 

Intuitive Surgical has fallen about 34% from its high and trades at 35x forward earnings, a drawdown that puts it on a list of names alongside Kinsale Capital. x.com 

Boston Scientific looks cheap on an estimate-based cash-earnings screen: 13x current and 12x next year's cash earnings versus 14x for medical-device makers imply a $43.85-$55.81 fair range against $42.04. This is a levels-only comparison using reported estimates, not fundamental diligence. x.com 

Costco, Apple, Intuitive Surgical, Alphabet and MSCI are amazing companies priced too high for their growth. Costco trades at 46x earnings on high-single-digit growth, Apple at 32x forward on low-double-digit EPS growth, and Intuitive Surgical at 38x forward on low-teens growth. Alphabet, the most attractive, is 33x operating income excluding investment gains. MSCI is 34x trailing on low-double-digit growth; S&P Global is better, cheaper and extremely high quality with similar growth. x.com  … Show more

Intuitive Surgical's 40% year-to-date drop is extremely disrespectful to one of the best businesses in the world, with revenue growing 19%. A model assuming 14% revenue CAGR, a 33% 2031 margin, a 38x P/E and 1% yearly buybacks gives a $487 fair value and a $535 one-year target, about 49% upside from $360. It is too far ahead of competitors, Chinese robots are unlikely to disrupt Western markets, and about 40x is fair, half the multiple of five years ago. x.com  x.com  x.com  x.com  x.com  x.com  x.com 

ClearPoint Neuro looks expensive against its sales, at 11x trailing and 8x next year's sales versus the roughly 5x medical-device makers usually get. Fair value is $7.16 to $9.11, about 5x next year's sales give or take 12%, putting the $13.83 price 52% above fair. The valuation leans on forecasts, with forward sales 40% above trailing. This is a levels-only read off reported earnings and revenue estimates, with no fundamental work. x.com